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Abstract
Background: Universal antiretroviral therapy (ART) for all pregnant/ breastfeeding women living with Human
Immunodeficiency Virus (HIV), known as Prevention of mother-to child transmission of HIV (PMTCT) Option
B+ (PMTCTB+), is being scaled up in most countries in Sub-Saharan Africa. In the transition to PMTCTB+, many countries
face challenges with proper implementation of the HIV care cascade. We aimed to describe the feasibility of a PMTCTB+
approach in the public health sector in Swaziland.
Methods: Lifelong ART was offered to a cohort of HIV+ pregnant women aged ≥16 years at the first antenatal care
(ANC1) visit in 9 public sector facilities, between 01/2013 and 06/2014. The study enrolment period was divided into 3
phases (early: 01–06/2013, mid: 07–12/2013 and late: 01–06/2014) to account for temporal trends. Kaplan-Meier estimates
and Cox proportional-hazards regression models were applied for ART initiation and attrition analyses.
Results: Of 665 HIV+ pregnant women, 496 (74.6%) initiated ART. ART initiation increased in later study enrolment
phases (mid: aHR: 1.41; later: aHR: 2.36), and decreased at CD4≥ 500 (aHR: 0.69). 52.9% were retained in care at 24 months.
Attrition was associated with ANC1 in the third trimester (aHR: 2.37), attending a secondary care facility (aHR: 1.98) and
ART initiation during later enrolment phases (mid aHR: 1.48; late aHR: 1.67). Of 373 women eligible, 67.3% received a first
VL. 223/251 (88.8%) were virologically suppressed (< 1000 copies/mL). Of 670 infants, 53.6% received an EID test, 320/359
had a test result recorded and of whom 7 (2.2%) were HIV+.
Conclusions: PMTCTB+ was found to be feasible in this setting, with high rates of maternal viral suppression and low
transmission to the infant. High treatment attrition, poor follow-up of mother-baby pairs and under-utilisation of VL and
EID testing are important programmatic challenges.
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Background
The use of antiretroviral drugs (ARVs) for prevention of
HIV transmission is widely accepted as a ‘Treatment as
Prevention’ strategy. Mono-therapy with Zidovudine
(AZT) and combined antiretroviral therapy (ART) are ef-
fective in reducing vertical HIV transmission from mother
to child [1–7]. Lifelong ART decreases morbidity and
mortality in adults across all CD4 counts [8, 9], protects
the foetus from HIV infection from the time of conception
in subsequent pregnancies and reduces the risk of trans-
mission to partners [10–12]. In 2013, the WHO recom-
mended the use of lifelong ART in all pregnant and
breastfeeding women at the time of HIV diagnosis regard-
less of CD4 count, known then as prevention of mother to
child transmission (PMTCT) option B+ (PMTCTB+) [13].
The HIV prevalence in Swaziland is estimated at 31%
among adults (18–49 years old) [14], and annual HIV
incidence is high at 2.5% [15]. HIV disproportionately
affects women and peaks at 49% in the age-group
25-29 years old [15] and is overall 41.1% among preg-
nant women [15, 16]. Until 2014, the Swaziland National
PMTCT Program applied the WHO PMTCTA ap-
proach, whereby women with CD4 < 350 and/or WHO
Stage 3/4 disease were eligible for lifelong ART. Women
not fulfilling these criteria were offered AZT from
14 weeks of gestation, AZT/3TC at delivery for one
week, followed by AZT until the end of the breastfeed-
ing period. The infants received Nevirapine syrup imme-
diately after delivery and for the duration of the
breastfeeding period or through 6 weeks if they were not
breastfed [17, 18]. In 2012 the reported PMTCTA cover-
age was > 80% and maternal to child transmission esti-
mated at 2.4% at 6 weeks [19].
In 2013, Médecins Sans Frontières (MSF) and the
Swaziland Ministry of Health initiated a PMTCTB+ im-
plementation study in the southern Shiselweni region.
The objective was to determine feasibility of PMTCTB+
in the public health sector and compile lessons learned
to inform national policy and scale-up. Interim results of
ART initiation rates during the early study implementa-
tion period have been described in detail elsewhere [20].
Here we present the final outcomes of this study from
the perspective of the pregnant women (ART initiation
and retention in care (RIC) rates, viral load (VL) testing
uptake and suppression) as well as of their exposed
infants (early infant diagnosis (EID) uptake, and HIV
transmission rates).
Methods
Setting
This was a prospective PMTCTB+ implementation cohort
study in Nhlangano health zone, southern Swaziland.
Predominantly rural, it comprises one secondary and 8
primary care facilities providing HIV diagnosis and ART
integrated into maternal and child health care services.
Full details of the setting and the study have been de-
scribed elsewhere [20].
From 28 January 2013 to 30 June 2014 newly diag-
nosed and previously known HIV+ pregnant women
aged ≥16 years were enrolled into the study and offered
lifelong ART at the first ante-natal care (ANC) visit. At
completion of study enrolment, PMTCTB+ was adopted
as the standard of care nationally, and the study follow-
up period coincided with the national roll out. Trained
HIV testing counsellors (HTCs) performed HIV testing,
treatment preparation, and ART follow-up counselling.
A serial rapid testing algorithm was applied using the
Alere Determine™ HIV-1/2 rapid test followed by the
Uni-Gold™ test on whole blood. Trained nurses initiated
ART and performed follow-up visits and ART refills,
while mobile medical doctors attended clinically compli-
cated HIV patients. Because PMTCTA remained the
standard of care nationally and per the guidance from
the Ministry of Health, women were still allowed to opt
for AZT in the PMTCTB+ study. Treatment response
was monitored through routine VL testing at 6 and
12 months and annually thereafter using the Biocentric
(Bandol, France) multi-manufacturer open platform for
HIV-1 VL quantification on plasma samples. Stepped-up
adherence counselling was performed in case of an
elevated VL > 1000 copies/ml [13]. EID testing was per-
formed using the Cobas® AmpliPrep/Cobas® TaqMan®
v2.0 for the qualitative detection of HIV-1 from heel
prick dried blood spots. Women missing their scheduled
ART refill visits or their EID appointment at 6 weeks after
birth were traced by phone as per national protocol.
Variables and definitions
First, for HIV+ pregnant treatment naïve women, the
primary outcome was time from first ANC visit to ART
initiation. Censoring occurred on the date of AZT
initiation, transfer out of the study facilities, death, loss
to follow-up (LTFU), and latest at 6 months after the
first ANC visit. Second, for women commencing ART,
the primary outcome was time to occurrence of the
composite unfavourable endpoint LTFU (defined as
≥4.5 months without visit) or death. Censoring occurred
at the last recorded clinic visit for transfer out and latest
at the end of the observation period (18 September
2015). Six-month VL test utilization was defined as the
proportion of women being on ART for at least 6 months
who received a VL test between 6 to 12 months after the
commencement of ART. Finally, EID utilization and HIV
mother to infant transmission were described. Because the
date of birth was often not recorded, EID was defined as
any PCR measurement done between birth and the end of
the observation period. HIV transmission was described
for infants who had EID test results available. For all
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analyses, baseline variables were measured at the time of
the first ANC visit. Same-day ART initiation was defined
as patients starting ART on the day of HIV diagnosis. The
study enrolment period was divided into 3 phases (early:
01–06/2013, mid: 07–12/2013 and late: 01–06/2014) to
account for temporal trends.
Data management and statistical analyses
Trained data clerks entered patient information into an
electronic study database. Clinical and socio-demographic
data were obtained from facility-based registers and
patient files. VL test results were obtained from the la-
boratory based electronic VL database, and birth out-
comes and EID data from maternity records and child
welfare registers. Baseline characteristics were described
using frequency statistics and proportions. Kaplan-Meier
estimates were computed and uni- and multivariate Cox
proportional-hazards regression models built for time to
ART initiation and treatment outcome analyses. All re-
gression models were adjusted for baseline socio-
demographic and clinical covariate information, and the
final models were obtained through backwards stepwise
regression and elimination of covariates with p > 0.15. All
analyses were performed using STATA (version 12.1) [21].
Results
Baseline characteristics
Overall, 665 HIV-positive pregnant women attended a
first ANC visit (Table 1) and 354 (53.2%) at primary care
facilities. The median age was 26 years (IQR: 23, 30), the
median CD4 count was 387 cells/μl (IQR: 264, 539), 506
(76.1%) had combined WHO stage I/II and 408 (61.4%)
were newly diagnosed HIV+. The median gestational age
was 22 weeks (IQR: 17, 26) and 131 (19.8%) were primi-
gravida. Overall one third of patients were enrolled
during each of the enrolment phases.
ART initiation
Of 665 HIV+ pregnant women, 496 (74.6%) initiated
ART (of whom 47 transitioned from single AZT ther-
apy), 70 (10.5%) opted for AZT and 99 (14.9%) received
neither. Of the 496 who initiated ART, 454 (91.5%) were
on a Tenofovir+Lamivudine+Efavirenz, 3 (0.6%) were on
Zidovudine+Lamivudine+Nevirapine, 3 (0.6%) were on
Zidovudine+Lamivudune+Efavirenz and 36 (7.3%)) were
missing ART regimen data. The proportion of women
initiating ART among all individuals increased from 150
(64.7%) to 198 (85.7%) between early to late study imple-
mentation phases. Kaplan-Meier estimates for same-day
ART initiation was 34.1% (95%CI: 30.7–37.9) and for
three-month ART initiation was 74.4% (95%CI:
71.1-77.7). The same-day and six-month ART initiation
rate increased from 8.6% (95%CI: 5.6–13.0) to 58.4%
(95%CI: 52.2–64.8) and 64.2% (95%CI 58.1–70.4) to
85.7% (95%CI 80.8–89.9; p < 0.001) respectively between
early and late enrolment phases (Fig. 1).
In multivariate analysis (Table 1), women with CD4 ≥ 500
(aHR: 0.69, 95%CI 0.56–0.87), missing CD4 (aHR: 0.31,
95% 0.2–0.49) and missing WHO staging result (aHR: 0.40,
95% 0.31–0.52) were less likely to initiate ART. The only
positive predictor of ART initiation was entry into the study
in later phases (mid: aHR: 1.41, 95% 1.12–1.77; late: aHR:
2.36, 95% 1.89–2.94).
ART outcomes
Of 496 women initiated on ART, 250 (50.4%) were in
care in the study clinics at the end of the observation
period, 4 (0.8%) had died and 37 (7.5%) had transferred
out. Of 205 (41.3%) women LTFU, 44/205 (21.5%) never
returned for the first drug refill visit. Of 94/205 (45.9%)
with recorded delivery date, 34 (36.2%) had the last drug
refill visit before delivery. Kaplan-Meier estimated
retention was 79.9% (95% CI 76–83.2), 70.7% (95% CI
66.4–74.6) and 52.9% (95% CI 47.6–57.9) at 6, 12 and
24 months. Retention between the CD4 categories was
different only for the first 3 months after ART initiation
(p = 0.01) but similar thereafter (p = 0.187). In the multi-
variate model (Table 2), ANC visit in the third trimester
(aHR: 2.37, 95% CI 1.39–4.01), secondary care facility
(aHR: 1.98, 95% CI 1.50–2.60) and later enrolment
phases (mid aHR: 1.48, 95% CI 1.05–2.08; late aHR: 1.67,
95% CI 1.18–2.37) were associated with an increased risk
of attrition while the risk was reduced for the age-group
25–34 years (aHR: 0.75, 95% 0.57–0.99). Following
defaulter tracing, 34 (40.5%) of 84 mothers traced from
those LTFU re-started ART after completion of the re-
tention analysis, and their median time of treatment
interruption was 5 months (IQR: 4.0, 7.3).
Viral load outcomes
Of 496 women initiated on ART, 373 were retained in
care for at least 6 months, making them eligible for a
first VL test. Of these 251 (67.3%) received a first VL
test and 223/251 (88.8%) were virologically suppressed
(< 1000 copies/mL).
Early infant diagnosis
Of 670 infants, 359 (53.6%) received a PCR EID HIV
test. A test result was available for 320 (89.1%) infants,
of whom 7 (2.2%) were HIV-positive: 3/278 (1.1%) for
women on ART, 2/34 (5.9%) for women on AZT and 2/
31 (6.5%) for women without ART/AZT; 4/141 (2.8%)
for women with CD4 < 350, 1/94 (1.1%) for CD4
350-499 and 1/85 (1.2%) for CD4 ≥ 500. For the 3 infants
who tested positive with their mothers on ART, all three
women had a suppressed VL test at the time of delivery
and the 3 infants received the EID test more than
2 months after delivery and were exclusively breastfed.
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Discussion
The roll out of PMTCTB+ was found to be feasible in
this setting. However, several challenges were encoun-
tered along the maternal treatment and infant diagnostic
cascade. Overall, three quarters of eligible women initi-
ated ART, but only half of them were retained on ART
at two years. While maternal VL suppression was high
and early mother to infant HIV transmission low, VL
utilization and EID testing uptake was sub-optimal.
ART initiation rates were low at the beginning of the
study but increased steadily over time. Several challenges
encountered during the early implementation of
PMTCTB+ may have played a role in this setting, such
as; patients’ and health workers’ resistance to lifelong
ART [20, 22, 23]. Other studies have also reported sig-
nificant barriers to ART uptake for PMTCT [23–25]
although this differs from the experience in Malawi
where a nationwide rollout and sensitization may have
improved awareness and uptake of the program [26]. As
this was a pilot study, no national sensitization could be
organized to promote ART acceptance specifically in
women who were not eligible for lifelong ART under
PMTCA [20]. In addition, AZT persisted as an option
during the entire study period because PMTCTA
remained the standard of care in the rest of the country.
These issues were addressed in response to early poor
ART uptake through repeated trainings for nurses and
community health workers and through intensified com-
munity awareness and mobilization activities.
Only 53% of women were retained in care at
24 months. Attrition was highest among HIV+ women
on ART at the secondary health care facility, among
women who initiated ART during the last trimester of
their pregnancy and for women with CD4 ≥ 500. These
findings are in line with other studies [26–31]. A pos-
sible explanation is that women only initiated ART for
the benefit of the unborn child, because they had limited
understanding of the subsequent benefit of ART for their
own health and in preventing transmission to their in-
fant during breastfeeding [32, 33]. In addition, 9% of
women receiving ART did not return for the first drug
refill, similar to findings from another study in Ethiopia
[31] which may reflect the importance of early treatment
adherence support and retention messages especially for
mothers with higher CD4 count at the start of their
treatment and clinical follow-up [23].
The risk of attrition was also higher among women
initiated on ART during the later enrolment phase which
had a higher proportion of same-day ART initiations.
Given that other observational studies have reported
higher risk of attrition in same-day initiates [31, 34], we
included this factor in the analysis as a possible predictor
of attrition. Although no association was discovered, we
still suggest that caution should be taken with same-day
ART initiation as a public health approach and patient
readiness should be taken into account [35].
In addition, context- and culture-specific factors prob-
ably play a major role in the attrition we observed. Many
Fig. 1 Kaplan-Meier graph of time to ART initiation stratified by CD4 group and implementation phases. *Early and late refers to the early
(01/2013 to 06/2013) and late (01/2014 to 06/2014) study enrolment periods
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facilities are located close to the South African border.
As pregnant women attending South African clinics are
given incentives after delivery, it is possible that some
mothers may have chosen to continue treatment there.
Furthermore, in their culture many Swazi women
continue to face structural barriers to ART initiation
and continuation such as gender inequality, economic
dependency and patriarchal social factors [36]. Women
often return to their mother’s homestead for delivery
and for the first few months of child rearing but move
Table 2 Characteristics of women who initiated ART and stopped ART under PMTCTB+, and factors associated with all cause ART attrition
Initiated ART, n (%) All cause attrition, n (%) cHR (95% CI) p aHR (95% CI) (n = 436) p
Total 496 209
CD4 (n = 496)
0–349 224 (45.2) 80 (38.3) Reference Reference
350–499 132 (26.6) 57 (27.3) 1.29 (0.92,1.82) 0.144 1.21 (0.88,1.66) 0.251
≥500 119 (24.0) 62 (29.6) 1.70 (1.22,2.37) 0.002 1.28 (0.92,1.78) 0.138
Missing 21 (4.2) 10 (4.8) 1.93 (1.00,3.73) 0.050 2.06 (0.98,4.34) 0.057
WHO (n = 496)
I + II 416 (83.9) 176 (84.2) Reference Reference
III + IV 11 (2.2) 5 (2.4) 1.24 (0.51,3.01) 0.639
Missing 69 (13.9) 28 (13.4) 1.23 (0.82,1.84) 0.317
Age group (n = 495)
16–24 197 (39.7) 96 (45.9) Reference Reference
25–34 260 (52.4) 97 (46.4) 0.70 (0.53,0.93) 0.014 0.75 (0.57,0.99) 0.046
≥35 38 (7.7) 16 (7.7) 0.86 (0.51,1.46) 0.580 0.99 (0.61,1.61) 0.979
Missing 1 (0.2) 0 (0) ___
HIV diagnosis (n = 492)
New 307 (61.9) 126 (60.3) Reference
Previously diagnosed 185 (37.3) 83 (39.7) 1.11 (0.84,1.47) 0.46
Missing 4 (0.8) 0 (0) ___
Trimester (n = 450)
1st 50 (10.1) 15 (7.2) Reference Reference
2nd 318 (64.1) 129 (61.7) 1.61 (0.93,2.80) 0.089 1.49 (0.94,2.38) 0.091
3rd 82 (16.5) 43 (20.6) 2.56 (1.40.4.68) 0.002 2.37 (1.39,4.01) 0.001
Missing 46 (9.3) 22 (10.5) ___
Pregnancy (n = 494)
1st 100 (21.2) 44 (21) Reference
≥2nd 394 (79.4) 164 (78.5) 0.87 (0.62,1.22) 0.419
Missing 2 (0.4) 1 (0.5) ___
Health care facility (n = 496)
Primary 253 (51.0) 90 (43.1) Reference Reference
Secondary 243 (49.0) 119 (56.9) 1.46 (1.11,1.92) 0.007 1.98 (1.50,2.60) < 0.001
ART initiation (n = 496)
Deferred 380 (76.6) 160 (76.6) Reference
Same-day 116 (23.4) 49 (23.4) 1.10 (0.80,1.52) 0.451
Enrolment phase (n = 496)
Early 150 (30.2) 63 (30.1) Reference
Mid 148 (29.8) 65 (31.1) 1.32 (0.93,1.88) 0.124 1.48 (1.05,2.08) 0.025
Late 198 (39.9) 81 (38.8) 1.50 (1.06,2.12) 0.024 1.67 (1.18,2.37) 0.004
cHR crude hazard ratio, aHR adjusted hazard ratio
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back to their own homes later. Future work could look
into the role of migration in treatment discontinuation
in this treatment group.
In this cohort, 67% of the women on ART received a
first VL after 6–12 months; of these 89% had an un-
detectable VL. To our knowledge, only one other study
has reported on VL outcomes of a PMTCTB+ cohort in
sub-Saharan Africa and reported similar findings [37].
VL monitoring was still quite a novel practice for health
workers and its routine use for treatment monitoring
was still not fully established [38]. In addition, according
to our data, women were often lost to follow-up before
they became eligible to receive their first VL at 6 months
after ART initiation. Nevertheless, the high proportion
of VL suppression among those tested was encouraging
and suggested good ART adherence in patients retained
and receiving a VL test. This is critical if ART is to pro-
vide long term benefits to the mothers and reduce the
risk of HIV transmission during breastfeeding [39–41].
EID test utilization was suboptimal at 54%. EID infor-
mation was collected from child welfare registers avail-
able at the facilities. Other authors have discussed the
problems with use of paper registers [42, 43]. The only
way to identify infants was if their mothers’ information
was included in the register, because of this, we may
have missed some poorly documented EID tests. Ac-
cording to program managers, often infants are brought
to the facility by another care giver (e.g.: grandmother),
who may not have the mother’s personal details. Health-
care workers prefer not to ask caregivers (other than the
biological mother) for permission to perform the HIV
test on the child, in order to avoid unintentional disclos-
ure of the mothers’ status. HIV status assessment in
children is expected to improve because Swaziland has
since adopted the WHO strategy to test all infants for
HIV regardless of exposure at 9 months after birth [44].
Vertical mother to child transmission rates were low
(2.2%) at 6 weeks (and comparable to the national esti-
mate of 2.4% [19]) and appeared lower when the mother
received ART (1.1%) when compared to AZT (5.9%) and
those without AZT/ART (6.5%). Transmission rates are
similar to findings from other studies [45–47]. These
data, however, need to be interpreted with caution be-
cause EID results were available for only less than half of
the eligible children.
This study has several limitations. First, routine paper
registers and patient files were the main data source.
Differences in recording practices may have led to varying
completeness and quality of data which limits internal val-
idity. This incompleteness also meant that we could not
include all possible confounding factors (e.g. income,
marital status and education) in our analyses limiting the
robustness of our findings. Second, misclassification of
the treatment outcome was possible. Although national
standard operating procedures required a routine phone
call three days after a missed appointment in order to re-
engage women into care or ascertain the outcome, 60% of
women could not be contacted due to incorrect contact
details (phone numbers did not exist, were unreachable,
or somebody else answered the phone). Weak ascertain-
ment of ART outcomes and suboptimal implementation
of physical defaulter tracing activities may have inflated
attrition rates [48, 49]. Third, this observational study was
likely affected by temporal trends such as patient and
community mobilization as well as countrywide adoption
and scale-up of PMTCTB+ in the second half of 2014. We
addressed this by dividing the study implementation
period into 3 phases. External validity is a strength of this
study. PMTCTB+ was implemented under routine condi-
tions in predominantly rural government clinics. There-
fore, limitations faced in this high HIV prevalence setting
likely apply to many other contexts in southern Africa.
Conclusions
Accelerated access to ART for pregnant women (PMTCTB
+) was feasible within a pilot implementation project under
routine public health service. While ART initiation rates in-
creased over time, high rates of ART attrition emerged as a
programmatic challenge. Documented maternal VL sup-
pression was high and vertical HIV transmission low, how-
ever, the uptake for VL and EID testing was suboptimal.
This, together with high attrition makes judgement of the
magnitude of the public health impact uncertain. Specific
aspects in PMTCTB+ programming need further strength-
ening, in particular, paying attention to community sensi-
tisation and training of staff, as well as to the continuity of
care and follow-up for both the mothers and their infants.
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